In health, the Coalition for Epidemic Preparedness Innovation (CEPI) said it has invested over $250 million in Lassa fever research since 2017 for the development of a vaccine against the deadly disease.
The CEPI’s Director of Epidemiology and Data Science, Gabrielle Breugelmans, disclosed on Wednesday at the inauguration of the Enable 1.5 cohort study in Abuja.
Enable 1.5 is a major research initiative designed to evaluate the incidence, symptoms, and co-infections of Lassa fever with malaria in West Africa.
The new research, led by the Nigeria Centre for Disease Control (NCDC), CEPI, and other partners, would commence in October at the designated sites in Ebonyi, Edo, and Ondo States, while it is scheduled to commence in Sierra Leone and Liberia in later weeks.
-9News Nigeria.
